Academic radiology · 2025
Comparison of Postoperative Adjuvant CTACE vs DEB-TACE Combined with Tislelizumab and Lenvatinib in BCLC Stage B/C Hepatocellular Carcinoma: A Propensity Score-Matched Analysis of Survival Outcomes.
СтатьяСравнительное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Yuan, Yang Liping, Li Xiaodong, Zhang Han, Jiang Honghan, Chen Kai, Shi Zhengrong
Аннотация
PURPOSE: This single-center, retrospective study aimed to compare the efficacy and safety of two adjuvant triple-therapy regimens-conventional transarterial chemoembolization (CTACE) versus drug-eluting bead TACE (DEB-TACE), each combined with tislelizumab and lenvatinib-in patients with BCLC stage B/C hepatocellular carcinoma (HCC) following curative resection.
METHODS: Using propensity score matching to minimize selection bias, we analyzed data from 211 eligible patients treated between March 2021 and June 2024. Key endpoints included overall survival (OS), progression-free survival (PFS), and adverse events (AEs).
RESULTS: After matching, the DEB-TACE-based regimen (DEB-TACE-T-L) was associated with significantly longer OS and PFS compared to the CTACE-based regimen (CTACE-T-L). In an exploratory subgroup analysis of 49 patients with microvascular invasion (MVI), those receiving DEB-TACE-T-L showed a promising trend toward improved survival outcomes; however, this finding should be interpreted as hypothesis-generating due to the limited sample size and lack of a statistically significant interaction between treatment type and MVI status. The safety profile was comparable between the two groups.
CONCLUSION: Our preliminary results suggest that adjuvant DEB-TACE-T-L may offer a survival benefit over CTACE-T-L in resected BCLC B/C HCC, with acceptable toxicity. The potential enhanced effect in MVI-positive patients observed here warrants further validation in larger, prospective studies.
METHODS: Using propensity score matching to minimize selection bias, we analyzed data from 211 eligible patients treated between March 2021 and June 2024. Key endpoints included overall survival (OS), progression-free survival (PFS), and adverse events (AEs).
RESULTS: After matching, the DEB-TACE-based regimen (DEB-TACE-T-L) was associated with significantly longer OS and PFS compared to the CTACE-based regimen (CTACE-T-L). In an exploratory subgroup analysis of 49 patients with microvascular invasion (MVI), those receiving DEB-TACE-T-L showed a promising trend toward improved survival outcomes; however, this finding should be interpreted as hypothesis-generating due to the limited sample size and lack of a statistically significant interaction between treatment type and MVI status. The safety profile was comparable between the two groups.
CONCLUSION: Our preliminary results suggest that adjuvant DEB-TACE-T-L may offer a survival benefit over CTACE-T-L in resected BCLC B/C HCC, with acceptable toxicity. The potential enhanced effect in MVI-positive patients observed here warrants further validation in larger, prospective studies.